Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

Stock Information for Immuron Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Immuron Limited

Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026
Biotricity to Host Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th
Health-E Commerce® and Biotricity® Collaborate to Expand Remote Cardiac Monitoring with Bioheart® for Flexible Spending Account (FSA) and Health Savings Account (HSA) Users
Biotricity and B-Secur Target the Consumer Wearables Market with Expansion of Next-Gen Cardiac Monitoring Platform
Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins
Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th
Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th
Biotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.